Enterprise Value

939.6M

Cash

723.5M

Avg Qtr Burn

N/A

Short % of Float

14.89%

Insider Ownership

0.34%

Institutional Own.

-

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
MVC-COV1901 Details
COVID-19 Vaccine

Approved

Update

Approved

Quarterly sales

Heplisav-B Details
Infectious disease, Hepatitis B vaccine, Hepatitis B

Approved

Quarterly sales

Approved

Quarterly sales

Heplisav-B Details
Infectious disease, Hepatitis B vaccine, Hepatitis B

BLA

Resubmission

Phase 2

Data readout

Z-1018 (adjuvanted w/ CpG 1018) Details
Shingles, Viral infection, Infectious disease

Phase 1/2

Data readout

Tdap-1018 (adjuvanted w/ CpG 1018) Details
Tetanus, diphtheria, and pertussis, Infectious disease

Phase 1

Data readout

VLA2001 Details
Infectious disease, COVID-19

Failed

Discontinued